Top Glove (TOPGLOV) Q3 2025 earnings summary

Executive summary

• 9MFY2025 revenue surged 55% YoY to MYR 2.6 billion, with sales volume up 65% and strong U.S. growth offsetting European declines.

• Q3 FY2025 revenue declined 6% QoQ to MYR 830 million, but sales volume rose 4% due to lower ASPs and a weaker USD.

• PATAMI for Q3 FY2025 was MYR 35 million, up 17% QoQ but down 31% YoY, including a MYR 30 million land disposal gain and a MYR 3 million forex loss.

• The group achieved a strong ESG score of 4.1/5, ranking in the top 10% globally in healthcare and number two in the global medical supply sector.

• The company remains optimistic about long-term prospects, focusing on quality, cost efficiency, and automation.

Financial highlights

• 3QFY2025 EBITDA was MYR 117 million, down 11% QoQ and 10% YoY; core EBITDA was MYR 91 million, down 32% QoQ.

• 9MFY2025 EBITDA rose 89% YoY to MYR 341 million; core EBITDA margin improved to 12% from 6% in 9MFY2024.

• Operating cash flow improved to MYR 78 million for Q3; net cash from operating activities for 9MFY2025 was MYR 121 million.

• Net borrowings reduced by 23% in Q3, with net gearing at 0.1x.

• No dividend was proposed for the current quarter.

Outlook and guidance

• Positive outlook for the glove industry, with expectations of stronger sales growth in Q4 FY2025 and robust long-term demand.

• Anticipates additional U.S. sales as tariff clarity improves; expects market conditions to stabilize over time.

• Raw material and energy prices expected to decline gradually, aiding cost optimization.

• Utilization rate increased to 65% in June, with further improvements targeted.

• Strategic manufacturing locations and a global customer base help mitigate supply chain and export risks.